Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT. What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade 1?

Trial Details

NCT ID
NCT05595447
Phase
PHASE2 / PHASE3
Sponsor
Hospital Regional de Alta Especialidad del Bajio
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Brentuximab Vedotin 50 MG [Adcetris]
Locations (sample)
  • León, Guanajuato, Mexico|21.12183,-101.68253

Key Eligibility Criteria

  • Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
  • Age ≥ 18 years and ≤ 90 years.
  • Adequate liver function, defined as:
  • Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →